Lung CancerNCT00450281
S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
An observational study of Lung Cancer, run by SWOG Cancer Research Network at 405 sites in United States.
Trial summary
RATIONALE: Studying samples of blood and tissue from smokers (closed to entry as of 7/15/07) and non-smokers with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. Read more about this study
- Who is it for?
- Ages 18 to 120 years
- Conditions the study is for
- Lung Cancer
- What is being tested?
- chromogenic in situ hybridization, gene expression analysis and mutation analysis
- Type of treatment
- Surgery or procedure
- How many people
- 981 participants
- Where
- 405 sitesUnited States
- Study dates
- Oct 2005to Jul 2012
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 120 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Cancer center
DISEASE CHARACTERISTICS:
- Histologically confirmed non-small cell lung cancer
- Stage I, II, IIIA, or IIIB (T4 or N3) disease
- No malignant pleural effusion; if pleural fluid is present, 1 of the following criteria must be met:
- Benign pleural fluid
- Pleural fluid is due to prior thoracotomy
- Pleural fluid is deemed too small to safely tap
- No diagnosis by cytology alone
- Newly diagnosed disease
- Must have tumor blocks/slides available and must be willing to provide tissue samples
- Prior smoking history meeting 1 of the following criteria:
- Never smoker, defined as < 100 cigarettes in lifetime
- Former smoker, defined as no smoking for ≥ 1 year
- Current smoker, defined as all others (closed to accrual as of 7/15/07)
- No pericardial effusions
PATIENT CHARACTERISTICS:
- No other prior malignancy except for 1 of the following:
- Adequately treated basal cell or squamous cell skin cancer
- In situ cervical cancer
- Other cancer for which the patient has been disease free for five years
PRIOR CONCURRENT THERAPY:
- No prior chemotherapy or radiotherapy
- Concurrent participation in therapeutic trials allowed
Trial locations and contacts
405 sites in 1 country.
300 sites in 1 country
United States300 sites
Hickman Cancer Center at Bixby Medical Center
Adrian, Michigan, 49221
McDowell Cancer Center at Akron General Medical Center
Akron, Ohio, 44307
Summa Center for Cancer Care at Akron City Hospital
Akron, Ohio, 44309-2090
Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
Allentown, Pennsylvania, 18105
Saint Anthony's Hospital at Saint Anthony's Health Center
Alton, Illinois, 62002
American Fork Hospital
American Fork, Utah, 84003
Providence Cancer Center
Anchorage, Alaska, 99508
AnMed Cancer Center
Anderson, South Carolina, 29621
Saint Joseph Mercy Cancer Center
Ann Arbor, Michigan, 48106-0995
CCOP - Michigan Cancer Research Consortium
Ann Arbor, Michigan, 48106
Hospital District Sixth of Harper County
Anthony, Kansas, 67003
Kaiser Permanente - Deer Valley
Antioch, California, 94531
Northwest Community Hospital
Arlington Heights, Illinois, 60005
Mission Hospitals - Memorial Campus
Asheville, North Carolina, 28801
Cancer Resource Center at King's Daughters Medical Center
Ashland, Kentucky, 41101-0151
Piedmont Hospital
Atlanta, Georgia, 30309
Northside Hospital Cancer Center
Atlanta, Georgia, 30342-1611
Saint Joseph's Hospital of Atlanta
Atlanta, Georgia, 30342-1701
CCOP - Atlanta Regional
Atlanta, Georgia, 30342
Sturdy Memorial Hospital
Attleboro, Massachusetts, 02703
Rush-Copley Cancer Care Center
Aurora, Illinois, 60504
WellStar Cobb Hospital
Austell, Georgia, 30106
Barberton Citizens Hospital
Barberton, Ohio, 44203
Bay Regional Medical Center
Bay City, Michigan, 48708
St. Francis Hospital and Health Centers - Beech Grove Campus
Beech Grove, Indiana, 46107
Mary Rutan Hospital
Bellefontaine, Ohio, 43311
St. Joseph Cancer Center
Bellingham, Washington, 98225
Mountainview Medical
Berlin Corners, Vermont, 05602
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
Northern Rockies Radiation Oncology Center
Billings, Montana, 59101
St. Vincent Healthcare Cancer Care Services
Billings, Montana, 59101
Hematology-Oncology Centers of the Northern Rockies - Billings
Billings, Montana, 59102
Billings Clinic - Downtown
Billings, Montana, 59107-7000
Bismarck Cancer Center
Bismarck, North Dakota, 58501
Medcenter One Hospital Cancer Care Center
Bismarck, North Dakota, 58501
Mid Dakota Clinic, PC
Bismarck, North Dakota, 58501
St. Alexius Medical Center Cancer Center
Bismarck, North Dakota, 58502
Bloomington Hospital Regional Cancer Institute
Bloomington, Indiana, 47403
Boston University Cancer Research Center
Boston, Massachusetts, 02118
Wood County Oncology Center
Bowling Green, Ohio, 43402
Bozeman Deaconess Cancer Center
Bozeman, Montana, 59715
Olympic Hematology and Oncology
Bremerton, Washington, 98310
Caritas St. Elizabeth's Medical Center
Brighton, Massachusetts, 02135-2997
Roswell Park Cancer Institute
Buffalo, New York, 14263-0001
Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center
Burbank, California, 91505
Fletcher Allen Health Care - University Health Center Campus
Burlington, Vermont, 05401
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
St. James Healthcare Cancer Care
Butte, Montana, 59701
Mercy Cancer Center at Mercy Medical Center
Canton, Ohio, 44708
Aultman Cancer Center at Aultman Hospital
Canton, Ohio, 44710-1799
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Rocky Mountain Oncology
Casper, Wyoming, 82609
Sandra L. Maxwell Cancer Center
Cedar City, Utah, 84720
Providence Centralia Hospital
Centralia, Washington, 98531-9027
Cancer Center of Kansas, PA - Chanute
Chanute, Kansas, 66720
Presbyterian Cancer Center at Presbyterian Hospital
Charlotte, North Carolina, 28233-3549
Martha Jefferson Hospital Cancer Care Center
Charlottesville, Virginia, 22901
H. Clay Evans Johnson Cancer Center at Memorial Hospital
Chattanooga, Tennessee, 37404
University of Illinois Cancer Center
Chicago, Illinois, 60612-7243
Veterans Affairs Medical Center - Chicago Westside Hospital
Chicago, Illinois, 60612
Creticos Cancer Center at Advocate Illinois Masonic Medical Center
Chicago, Illinois, 60657
Adena Regional Medical Center
Chillicothe, Ohio, 45601
Marshfield Clinic - Chippewa Center
Chippewa Falls, Wisconsin, 54729
Good Samaritan Hospital Cancer Treatment Center
Cincinnati, Ohio, 45220
Bethesda North Hospital
Cincinnati, Ohio, 45242
Clackamas Radiation Oncology Center
Clackamas, Oregon, 97015
North Coast Cancer Care - Clyde
Clyde, Ohio, 43410
Memorial Hospital Cancer Center - Colorado Springs
Colorado Springs, Colorado, 80909
John B. Amos Cancer Center
Columbus, Georgia, 31904
Riverside Methodist Hospital Cancer Care
Columbus, Ohio, 43214-3998
CCOP - Columbus
Columbus, Ohio, 43215
Grant Medical Center Cancer Care
Columbus, Ohio, 43215
Mount Carmel Health - West Hospital
Columbus, Ohio, 43222
Doctors Hospital at Ohio Health
Columbus, Ohio, 43228
Cancer Care Center at John Muir Health - Concord Campus
Concord, California, 94524-4110
New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care
Concord, New Hampshire, 03301
Mercy and Unity Cancer Center at Mercy Hospital
Coon Rapids, Minnesota, 55433
Danville Regional Medical Center
Danville, Virginia, 24541
Genesis Regional Cancer Center at Genesis Medical Center
Davenport, Iowa, 52803
Grandview Hospital
Dayton, Ohio, 45405
Good Samaritan Hospital
Dayton, Ohio, 45406
David L. Rike Cancer Center at Miami Valley Hospital
Dayton, Ohio, 45409
Samaritan North Cancer Care Center
Dayton, Ohio, 45415
CCOP - Dayton
Dayton, Ohio, 45420
Oakwood Cancer Center at Oakwood Hospital and Medical Center
Dearborn, Michigan, 48123-2500
Charles B. Eberhart Cancer Center at DeKalb Medical Center
Decatur, Georgia, 30033
Decatur Memorial Hospital Cancer Care Institute
Decatur, Illinois, 62526
Grady Memorial Hospital
Delaware, Ohio, 43015
Kaiser Permanente - Denver
Denver, Colorado, 80205
Cancer Center of Kansas, PA - Dodge City
Dodge City, Kansas, 67801
Duluth Clinic Cancer Center - Duluth
Duluth, Minnesota, 55805-1983
CCOP - Duluth
Duluth, Minnesota, 55805
Miller - Dwan Medical Center
Duluth, Minnesota, 55805
St. Luke's Hospital Cancer Care Center
Duluth, Minnesota, 55805
Cancer Centers of the Carolinas - Easley
Easley, South Carolina, 29640
Center for Cancer Treatment & Prevention at Sacred Heart Hospital
Eau Claire, Wisconsin, 54701
Marshfield Clinic Cancer Care at Regional Cancer Center
Eau Claire, Wisconsin, 54701
Fairview Southdale Hospital
Edina, Minnesota, 55435
Cancer Center of Kansas, PA - El Dorado
El Dorado, Kansas, 67042
Community Cancer Center
Elyria, Ohio, 44035
Hematology Oncology Center
Elyria, Ohio, 44035
Green Bay Oncology, Limited - Escanaba
Escanaba, Michigan, 49431
Evanston Hospital
Evanston, Illinois, 60201-1781
North Bay Cancer Center
Fairfield, California, 94533
St. Francis Hospital
Federal Way, Washington, 98003
Blanchard Valley Medical Associates
Findlay, Ohio, 45840
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Hurley Medical Center
Flint, Michigan, 48503
Poudre Valley Hospital
Fort Collins, Colorado, 80524
Front Range Cancer Specialists
Fort Collins, Colorado, 80528
Dwight David Eisenhower Army Medical Center
Fort Gordon, Georgia, 30905-5650
Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital
Fort Lauderdale, Florida, 33308
Cancer Center of Kansas - Fort Scott
Fort Scott, Kansas, 66701
Hembree Mercy Cancer Center at St. Edward Mercy Medical Center
Fort Smith, Arkansas, 72903
Middletown Regional Hospital
Franklin, Ohio, 45005-1066
Fredericksburg Oncology, Incorporated
Fredericksburg, Virginia, 22401
Kaiser Permanente - Fremont
Fremont, California, 94538
Mercy and Unity Cancer Center at Unity Hospital
Fridley, Minnesota, 55432
Northeast Georgia Medical Center
Gainesville, Georgia, 30501
CaroMont Cancer Center at Gaston Memorial Hospital
Gastonia, North Carolina, 28053
Glendale Memorial Hospital Comprehensive Cancer Center
Glendale, California, 91204
Wayne Memorial Hospital, Incorporated
Goldsboro, North Carolina, 27534
Big Sky Oncology
Great Falls, Montana, 59405-5309
Great Falls Clinic - Main Facility
Great Falls, Montana, 59405
Sletten Cancer Institute at Benefis Healthcare
Great Falls, Montana, 59405
Study site
Great Falls, Montana, 59405
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
Green Bay, Wisconsin, 54301-3526
Green Bay Oncology, Limited at St. Mary's Hospital
Green Bay, Wisconsin, 54303
St. Mary's Hospital Medical Center - Green Bay
Green Bay, Wisconsin, 54303
St. Vincent Hospital Regional Cancer Center
Green Bay, Wisconsin, 54307-3508
Wayne Hospital
Greenville, Ohio, 45331
Bon Secours St. Francis Health System
Greenville, South Carolina, 29601
Cancer Centers of the Carolinas - Faris Road
Greenville, South Carolina, 29605
Cancer Centers of the Carolinas - Grove Commons
Greenville, South Carolina, 29605
Greenville Hospital Cancer Center
Greenville, South Carolina, 29605
Cancer Centers of the Carolinas - Eastside
Greenville, South Carolina, 29615
CCOP - Greenville
Greenville, South Carolina, 29615
Self Regional Cancer Center at Self Regional Medical Center
Greenwood, South Carolina, 29646
Cancer Centers of the Carolinas - Greer Medical Oncology
Greer, South Carolina, 29650
Cancer Centers of the Carolinas - Greer Radiation Oncology
Greer, South Carolina, 29650
Van Elslander Cancer Center at St. John Hospital and Medical Center
Grosse Pointe Woods, Michigan, 48236
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
Hartford, Connecticut, 06105
Ingalls Cancer Care Center at Ingalls Memorial Hospital
Harvey, Illinois, 60426
Northern Montana Hospital
Havre, Montana, 59501
Hays Medical Center
Hays, Kansas, 67601
Kaiser Permanente Medical Center - Hayward
Hayward, California, 94545
St. Peter's Hospital
Helena, Montana, 59601
Pardee Memorial Hospital
Hendersonville, North Carolina, 28791
High Point Regional Hospital
High Point, North Carolina, 27261
Kaiser Permanente - Moanalua Medical Center and Clinic
Honolulu, Hawaii, 96819
Tripler Army Medical Center
Honolulu, Hawaii, 96859
New Hampshire Oncology - Hematology, PA - Hooksett
Hooksett, New Hampshire, 03106
Hutchinson Hospital Corporation
Hutchinson, Kansas, 65702
Hutchinson Area Health Care
Hutchinson, Minnesota, 55350
Cancer Center of Kansas-Independence
Independence, Kansas, 67301
Dickinson County Healthcare System
Iron Mountain, Michigan, 49801
Foote Memorial Hospital
Jackson, Michigan, 49201
Ella Milbank Foshay Cancer Center at Jupiter Medical Center
Jupiter, Florida, 33458
Borgess Medical Center
Kalamazoo, Michigan, 49001
West Michigan Cancer Center
Kalamazoo, Michigan, 49007-3731
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
Glacier Oncology, PLLC
Kalispell, Montana, 59901
Kalispell Medical Oncology at KRMC
Kalispell, Montana, 59901
Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
Kansas City, Kansas, 66160-7357
Truman Medical Center - Hospital Hill
Kansas City, Missouri, 64108
Saint Luke's Cancer Institute at Saint Luke's Hospital
Kansas City, Missouri, 64111
St. Joseph Medical Center
Kansas City, Missouri, 64114
North Kansas City Hospital
Kansas City, Missouri, 64116
Heartland Hematology Oncology Associates, Incorporated
Kansas City, Missouri, 64118
CCOP - Kansas City
Kansas City, Missouri, 64131
Research Medical Center
Kansas City, Missouri, 64132
Columbia Basin Hematology
Kennewick, Washington, 99336
Charles F. Kettering Memorial Hospital
Kettering, Ohio, 45429
Cancer Center of Kansas, PA - Kingman
Kingman, Kansas, 67068
Thompson Cancer Survival Center
Knoxville, Tennessee, 37916
U.T. Medical Center Cancer Institute
Knoxville, Tennessee, 37920-6999
La Grange Memorial Hospital
La Grange, Illinois, 60525
Lakes Region General Hospital
Laconia, New Hampshire, 03246
Kaiser Permanente - Lafayette
Lafayette, Colorado, 80026
Haematology-Oncology Associates of Ohio and Michigan, PC
Lambertville, Michigan, 48144
Fairfield Medical Center
Lancaster, Ohio, 43130
Breslin Cancer Center at Ingham Regional Medical Center
Lansing, Michigan, 48910
Sparrow Regional Cancer Center
Lansing, Michigan, 48912-1811
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
Gwinnett Medical Center
Lawrenceville, Georgia, 30045
Saint Luke's East - Lee's Summit
Lee's Summit, Missouri, 64086
Cancer Center of Kansas, PA - Liberal
Liberal, Kansas, 67905
Liberty Hospital
Liberty, Missouri, 64068
St. Rita's Medical Center
Lima, Ohio, 45801
Lima Memorial Hospital
Lima, Ohio, 45804
St. Mary Mercy Hospital
Livonia, Michigan, 48154
Logan Regional Hospital
Logan, Utah, 84321
Jewish Hospital
Louisville, Kentucky, 40202-1886
Elliot Regional Cancer Center at Elliot Hospital
Manchester, New Hampshire, 03103
CCOP - North Shore University Hospital
Manhasset, New York, 11030
Don Monti Comprehensive Cancer Center at North Shore University Hospital
Manhasset, New York, 11030
Holy Family Memorial Medical Center Cancer Care Center
Manitowoc, Wisconsin, 54221-1450
HealthEast Cancer Care at St. John's Hospital
Maplewood, Minnesota, 55109
Minnesota Oncology Hematology, PA - Maplewood
Maplewood, Minnesota, 55109
Kennestone Cancer Center at Wellstar Kennestone Hospital
Marietta, Georgia, 30060
Strecker Cancer Center at Marietta Memorial Hospital
Marietta, Ohio, 45750
Bay Area Cancer Care Center at Bay Area Medical Center
Marinette, Wisconsin, 54143
Marshfield Clinic - Marshfield Center
Marshfield, Wisconsin, 54449
Saint Joseph's Hospital
Marshfield, Wisconsin, 54449
Tibotec Therapeutics - Division of Ortho Biotech Products, LP
Marysville, California, 95901
Mercy Cancer Center at Mercy Medical Center - North Iowa
Mason City, Iowa, 50401
Northwest Ohio Oncology Center
Maumee, Ohio, 43537-1839
Cardinal Bernardin Cancer Center at Loyola University Medical Center
Maywood, Illinois, 60153
Caritas Holy Family Hospital
Methuen, Massachusetts, 01844
CCOP - Mount Sinai Medical Center
Miami Beach, Florida, 33140
Saint Anthony Memorial Health Centers
Michigan City, Indiana, 46360
Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center
Milwaukee, Wisconsin, 53215
Veterans Affairs Medical Center - Milwaukee
Milwaukee, Wisconsin, 53295
Providence Milwaukie Hospital
Milwaukie, Oregon, 97222
Winthrop University Hospital
Mineola, New York, 11501
Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center - Minneapolis
Minneapolis, Minnesota, 55415
Marshfield Clinic - Lakeland Center
Minocqua, Wisconsin, 54548
Trinity CancerCare Center
Minot, North Dakota, 58701
Guardian Oncology and Center for Wellness
Missoula, Montana, 59804
Montana Cancer Specialists at Montana Cancer Center
Missoula, Montana, 59807-7877
Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
Missoula, Montana, 59807
Louisiana State University Health Sciences Center - Monroe
Monroe, Louisiana, 71210
Community Cancer Center of Monroe
Monroe, Michigan, 48162
Mercy Memorial Hospital - Monroe
Monroe, Michigan, 48162
Clemens Regional Medical Center
Mount Clemens, Michigan, 48043
Good Samaritan Regional Health Center
Mount Vernon, Illinois, 62864
Knox Community Hospital
Mount Vernon, Ohio, 43050
Skagit Valley Hospital Cancer Care Center
Mount Vernon, Washington, 98273
Jon and Karen Huntsman Cancer Center at Intermountain Medical Center
Murray, Utah, 84157
Edward Hospital Cancer Center
Naperville, Illinois, 60540
Saint Peter's University Hospital
New Brunswick, New Jersey, 08901
Long Island Jewish Medical Center
New Hyde Park, New York, 11040
Beth Israel Medical Center - Petrie Division
New York, New York, 10003-3803
St. Luke's - Roosevelt Hospital Center - St.Luke's Division
New York, New York, 10025
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
New York, New York, 10032
Licking Memorial Cancer Care Program at Licking Memorial Hospital
Newark, Ohio, 43055
Providence Newberg Medical Center
Newberg, Oregon, 97132
Cancer Center of Kansas, PA - Newton
Newton, Kansas, 67114
Fisher-Titus Medical Center
Norwalk, Ohio, 44857
Caritas Norwood Hospital
Norwood, Massachusetts, 02062
Kaiser Permanente Medical Center - Oakland
Oakland, California, 94611
Green Bay Oncology, Limited - Oconto Falls
Oconto Falls, Wisconsin, 54154
Val and Ann Browning Cancer Center at McKay-Dee Hospital Center
Ogden, Utah, 84403
Providence St. Peter Hospital Regional Cancer Center
Olympia, Washington, 98506-5166
Methodist Estabrook Cancer Center
Omaha, Nebraska, 68114
Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
Orange, California, 92868
St. Charles Mercy Hospital
Oregon, Ohio, 43616
Toledo Clinic - Oregon
Oregon, Ohio, 43616
Willamette Falls Hospital
Oregon City, Oregon, 97045
M.D. Anderson Cancer Center at Orlando
Orlando, Florida, 32806
McCreery Cancer Center at Ottumwa Regional
Ottumwa, Iowa, 52501
Menorah Medical Center
Overland Park, Kansas, 66209
Saint Luke's Hospital - South
Overland Park, Kansas, 66213
Cancer Center of Kansas, PA - Parsons
Parsons, Kansas, 67357
Regional Cancer Center at Singing River Hospital
Pascagoula, Mississippi, 39581
Mount Carmel Regional Cancer Center
Pittsburg, Kansas, 66762
Allegheny Cancer Center at Allegheny General Hospital
Pittsburgh, Pennsylvania, 15212
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
Pittsburgh, Pennsylvania, 15224-1791
Valley Care Medical Center
Pleasanton, California, 94588
Robert and Beverly Lewis Family Cancer Care Center at Pomona Valley Hospital Medical Center
Pomona, California, 91767
St. Joseph Mercy Oakland
Pontiac, Michigan, 48341-2985
Mercy Regional Cancer Center at Mercy Hospital
Port Huron, Michigan, 48060
Providence Cancer Center at Providence Portland Medical Center
Portland, Oregon, 97213-2967
Adventist Medical Center
Portland, Oregon, 97216
CCOP - Columbia River Oncology Program
Portland, Oregon, 97225
Providence St. Vincent Medical Center
Portland, Oregon, 97225
Knight Cancer Institute at Oregon Health and Science University
Portland, Oregon, 97239-3098
Harrison Poulsbo Hematology and Onocology
Poulsbo, Washington, 98370
Cancer Center of Kansas, PA - Pratt
Pratt, Kansas, 67124
Utah Valley Regional Medical Center - Provo
Provo, Utah, 84604
Good Samaritan Cancer Center
Puyallup, Washington, 98372
All Saints Cancer Center at Wheaton Franciscan Healthcare
Racine, Wisconsin, 53405
Kaiser Permanente Medical Center - Redwood City
Redwood City, California, 94063
Ministry Medical Group at Saint Mary's Hospital
Rhinelander, Wisconsin, 54501
Marshfield Clinic - Indianhead Center
Rice Lake, Wisconsin, 54868
Kaiser Permanente Medical Center - Richmond
Richmond, California, 94801
Reid Hospital & Health Care Services
Richmond, Indiana, 47374
Southern Regional Medical Center
Riverdale, Georgia, 30274-2600
Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center
Robbinsdale, Minnesota, 55422-2900
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905
Highland Hospital of Rochester
Rochester, New York, 14620
Lipson Cancer and Blood Center at Rochester General Hospital
Rochester, New York, 14621
James P. Wilmot Cancer Center at University of Rochester Medical Center
Rochester, New York, 14642
Harbin Clinic Cancer Center - Medical Oncology
Rome, Georgia, 30165
Kaiser Permanente Medical Center - Roseville
Roseville, California, 95661
William Beaumont Hospital - Royal Oak Campus
Royal Oak, Michigan, 48073
University of California Davis Cancer Center
Sacramento, California, 95817
Mercy General Hospital
Sacramento, California, 95819
Kaiser Permanente Medical Center - Sacramento
Sacramento, California, 95825
Seton Cancer Institute at Saint Mary's - Saginaw
Saginaw, Michigan, 48601
Heartland Regional Medical Center
Saint Joseph, Missouri, 64506
Saint Joseph Oncology, Incorporated
Saint Joseph, Missouri, 64507
CCOP - Metro-Minnesota
Saint Louis Park, Minnesota, 55416
Park Nicollet Cancer Center
Saint Louis Park, Minnesota, 55416
Regions Hospital Cancer Care Center
Saint Paul, Minnesota, 55101
United Hospital
Saint Paul, Minnesota, 55102
Cancer Care Center, Incorporated
Salem, Ohio, 44460
Cancer Center of Kansas, PA - Salina
Salina, Kansas, 67401
LDS Hospital
Salt Lake City, Utah, 84103
About this study
Official title: Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men
RATIONALE: Studying samples of blood and tissue from smokers (closed to entry as of 7/15/07) and non-smokers with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors learn more about risk factors for lung cancer and may help the study of cancer in the future.
PURPOSE: This clinical trial is studying carcinogens in lung tissue from smokers (closed to entry as of 7/15/07) and non-smokers with newly diagnosed stage I, stage II, or stage III non-small cell lung cancer.
Read the detailed description
OBJECTIVES:
- Assess lung tissue from patients with stage I, stage II, stage IIIA, or stage IIIB non-small cell lung cancer for specific tobacco smoke carcinogens (including polycyclic aromatic hydrocarbons [PAH] and DNA adducts, alterations in specific genes, including p53 and K-ras, and expression of HER2 and estrogen receptors α and β).
- Determine whether tobacco smoke carcinogens differ by gender and smoking status, adjusting for potential exposures and influential factors, including family smoking status, medication use, and hormonal and reproductive factors.
- Measure the levels of PAH-DNA adducts in lymphocytes and lung tissue and examine correlations between the two tissue sources.
- Determine whether DNA damage levels in tissue as well as in lymphocytes are higher in females than in males for the same level of smoking.
- Determine polymorphisms in several genes involved in the metabolism of the specific carcinogens investigated and in steroidogenesis and metabolism.
- Summarize patient self-report questionnaire data on active and passive smoking, other carcinogenic exposures, smoking preference, economic and educational status, family smoking status, reproductive factors, weight loss, and medication use by categories of male versus female and never-smoker versus ever-smoker.
OUTLINE: This is a case-series, multicenter study. Patients are stratified according to gender and smoking status (never smoker [< 100 cigarettes smoked during lifetime] vs ever smoker [≥ 100 cigarettes smoked during lifetime] [closed to accrual as of 7/15/07]).
Patients complete the Lung Cancer Epidemiology Questionnaire for detailed assessment of the following:
- Exposure to active and passive smoke
- Occupational exposures
- Reproductive and hormonal risk factors
- Weight loss
- Economic and educational status
- Family smoking status
- Medication use
- Other variables relevant for the analysis (e.g., HER2, estrogen receptor status) Peripheral blood samples are collected for research studies. Previously collected tissue samples are also studied in the laboratory. Samples are examined for DNA adduct levels. Estrogen receptor α and β are assessed by immunohistochemistry (IHC). HER2 expression and amplification are measured by chromogenic in situ hybridization. IHC and DNA-polymerase chain reaction (PCR)-single-stranded conformational polymorphism assay are used to analyze p53 mutations. RAS mutations are analyzed with restriction fragment length polymorphism-PCR assay. Polycyclic aromatic hydrocarbons and 4-aminobiphenyl-DNA damage are assessed by IHC and immunofluorescence. Matrix-assisted laser desorption/ionization time of flight mass spectrometry is used to genotype polymorphisms, including CYP1A1, CYP1B1, GSTM1, GSTP1, MPO, NAT-1, NAT-2, CYP19, CYP17, SULT1A1.
Patients are followed annually for up to 5 years.
PROJECTED ACCRUAL: A total of 900 patients will be accrued for this study (female and male smoker strata closed to accrual as of 7/15/07).
- Conditions
- Lung Cancer
- Being tested
- chromogenic in situ hybridization, gene expression analysis, mutation analysis, polymerase chain reaction, polymorphism analysis
- Keywords
- stage IIIB non-small cell lung cancer, stage IIIA non-small cell lung cancer, stage IA non-small cell lung cancer, stage IB non-small cell lung cancer, stage IIA non-small cell lung cancer, stage IIB non-small cell lung cancer
- Medical subject headings
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
chromogenic in situ hybridizationGenetic
gene expression analysisGenetic
mutation analysisGenetic
polymerase chain reactionGenetic
polymorphism analysisGenetic
fluorescent antibody techniqueOther
laboratory biomarker analysisOther
matrix-assisted laser desorption/ionization time of flight mass spectrometryOther
study of socioeconomic and demographic variablesOther
study of high risk factorsProcedure or surgery
| Study group | Role | What they receive |
|---|---|---|
| Male, Never-smokers | Male subjects who smoked less than 100 cigarettes during their lifetime. Receives: Genetic: chromogenic in situ hybridization; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: fluorescent antibody technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry; Other: study of socioeconomic and demographic variables; Procedure: study of high risk factors | |
| Male, Ever-smokers | Male subjects who have smoked at least 100 cigarettes during their lifetime. Receives: Genetic: chromogenic in situ hybridization; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: fluorescent antibody technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry; Other: study of socioeconomic and demographic variables; Procedure: study of high risk factors | |
| Female, Ever-smokers | Female subjects who have smoked less than 100 cigarettes during their lifetime. Receives: Genetic: chromogenic in situ hybridization; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: fluorescent antibody technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry; Other: study of socioeconomic and demographic variables; Procedure: study of high risk factors | |
| Female, Never-smokers | Female subjects who have smoked at least 100 cigarettes during their lifetime. Receives: Genetic: chromogenic in situ hybridization; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: fluorescent antibody technique; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry; Other: study of socioeconomic and demographic variables; Procedure: study of high risk factors |
What is being measured
The primary outcome is the main question the study is designed to answer.
DNA adduct levels
Measured: End of study
Tumor tissue alterations
Measured: End of study
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Mar 2007 (estimated)
- Study startOct 2005
- Primary completionJul 2012
- Study completionJul 2012
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- More trials run by SWOG Cancer Research NetworkThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 981 participants (actual)
Sponsor and investigators
- Lead sponsor
- SWOG Cancer Research Network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Christine B. Ambrosone, PhD, Study chair, Roswell Park Cancer InstituteRegina M. Santella, PhD, Study chair, Herbert Irving Comprehensive Cancer CenterKathy S. Albain, MD, Study chair, Loyola UniversityPaul H. Gumerlock, PhD, Study chair, University of California, Davis
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00450281
- Sponsor's protocol ID
- CDR0000446084
- Other IDs
- S0424, U10CA032102
- Status last verified
- Dec 2013
- First submitted
- 20 Mar 2007
- Last updated
- 26 Oct 2015
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 26 Oct 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men
- ClinicalTrials.gov ID
- NCT00450281
- Acronym / sponsor ID
- CDR0000446084
- Conditions
- Lung Cancer
- Keywords
- stage IIIB non-small cell lung cancer, stage IIIA non-small cell lung cancer, stage IA non-small cell lung cancer, stage IB non-small cell lung cancer, stage IIA non-small cell lung cancer, stage IIB non-small cell lung cancer
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 981 participants (actual)
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Collaborators
- National Cancer Institute (NCI)
- Study start
- Oct 2005
- Primary completion
- Jul 2012 (actual)
- Study completion
- Jul 2012 (actual)
- First posted
- 22 Mar 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Studying samples of blood and tissue from smokers (closed to entry as of 7/15/07) and non-smokers with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors learn more about risk factors for lung cancer and may help the study of cancer in the future.
PURPOSE: This clinical trial is studying carcinogens in lung tissue from smokers (closed to entry as of 7/15/07) and non-smokers with newly diagnosed stage I, stage II, or stage III non-small cell lung cancer.
Detailed description
OBJECTIVES:
- Assess lung tissue from patients with stage I, stage II, stage IIIA, or stage IIIB non-small cell lung cancer for specific tobacco smoke carcinogens (including polycyclic aromatic hydrocarbons [PAH] and DNA adducts, alterations in specific genes, including p53 and K-ras, and expression of HER2 and estrogen receptors α and β).
- Determine whether tobacco smoke carcinogens differ by gender and smoking status, adjusting for potential exposures and influential factors, including family smoking status, medication use, and hormonal and reproductive factors.
- Measure the levels of PAH-DNA adducts in lymphocytes and lung tissue and examine correlations between the two tissue sources.
- Determine whether DNA damage levels in tissue as well as in lymphocytes are higher in females than in males for the same level of smoking.
- Determine polymorphisms in several genes involved in the metabolism of the specific carcinogens investigated and in steroidogenesis and metabolism.
- Summarize patient self-report questionnaire data on active and passive smoking, other carcinogenic exposures, smoking preference, economic and educational status, family smoking status, reproductive factors, weight loss, and medication use by categories of male versus female and never-smoker versus ever-smoker.
OUTLINE: This is a case-series, multicenter study. Patients are stratified according to gender and smoking status (never smoker [< 100 cigarettes smoked during lifetime] vs ever smoker [≥ 100 cigarettes smoked during lifetime] [closed to accrual as of 7/15/07]).
Patients complete the Lung Cancer Epidemiology Questionnaire for detailed assessment of the following:
- Exposure to active and passive smoke
- Occupational exposures
- Reproductive and hormonal risk factors
- Weight loss
- Economic and educational status
- Family smoking status
- Medication use
- Other variables relevant for the analysis (e.g., HER2, estrogen receptor status) Peripheral blood samples are collected for research studies. Previously collected tissue samples are also studied in the laboratory. Samples are examined for DNA adduct levels. Estrogen receptor α and β are assessed by immunohistochemistry (IHC). HER2 expression and amplification are measured by chromogenic in situ hybridization. IHC and DNA-polymerase chain reaction (PCR)-single-stranded conformational polymorphism assay are used to analyze p53 mutations. RAS mutations are analyzed with restriction fragment length polymorphism-PCR assay. Polycyclic aromatic hydrocarbons and 4-aminobiphenyl-DNA damage are assessed by IHC and immunofluorescence. Matrix-assisted laser desorption/ionization time of flight mass spectrometry is used to genotype polymorphisms, including CYP1A1, CYP1B1, GSTM1, GSTP1, MPO, NAT-1, NAT-2, CYP19, CYP17, SULT1A1.
Patients are followed annually for up to 5 years.
PROJECTED ACCRUAL: A total of 900 patients will be accrued for this study (female and male smoker strata closed to accrual as of 7/15/07).
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Male, Never-smokers | – | Genetic: chromogenic in situ hybridization, Genetic: gene expression analysis, Genetic: mutation analysis, Genetic: polymerase chain reaction, Genetic: polymorphism analysis, Other: fluorescent antibody technique, Other: immunohistochemistry staining method, Other: laboratory biomarker analysis, Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry, Other: study of socioeconomic and demographic variables, Procedure: study of high risk factorsMale subjects who smoked less than 100 cigarettes during their lifetime. |
| Male, Ever-smokers | – | Genetic: chromogenic in situ hybridization, Genetic: gene expression analysis, Genetic: mutation analysis, Genetic: polymerase chain reaction, Genetic: polymorphism analysis, Other: fluorescent antibody technique, Other: immunohistochemistry staining method, Other: laboratory biomarker analysis, Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry, Other: study of socioeconomic and demographic variables, Procedure: study of high risk factorsMale subjects who have smoked at least 100 cigarettes during their lifetime. |
| Female, Ever-smokers | – | Genetic: chromogenic in situ hybridization, Genetic: gene expression analysis, Genetic: mutation analysis, Genetic: polymerase chain reaction, Genetic: polymorphism analysis, Other: fluorescent antibody technique, Other: immunohistochemistry staining method, Other: laboratory biomarker analysis, Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry, Other: study of socioeconomic and demographic variables, Procedure: study of high risk factorsFemale subjects who have smoked less than 100 cigarettes during their lifetime. |
| Female, Never-smokers | – | Genetic: chromogenic in situ hybridization, Genetic: gene expression analysis, Genetic: mutation analysis, Genetic: polymerase chain reaction, Genetic: polymorphism analysis, Other: fluorescent antibody technique, Other: immunohistochemistry staining method, Other: laboratory biomarker analysis, Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry, Other: study of socioeconomic and demographic variables, Procedure: study of high risk factorsFemale subjects who have smoked at least 100 cigarettes during their lifetime. |
Who may qualify
- Ages
- 18 to 120 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Cancer center
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| chromogenic in situ hybridization | Genetic | Female, Ever-smokers, Female, Never-smokers, Male, Ever-smokers, Male, Never-smokers |
| gene expression analysis | Genetic | Female, Ever-smokers, Female, Never-smokers, Male, Ever-smokers, Male, Never-smokers |
| mutation analysis | Genetic | Female, Ever-smokers, Female, Never-smokers, Male, Ever-smokers, Male, Never-smokers |
| polymerase chain reaction | Genetic | Female, Ever-smokers, Female, Never-smokers, Male, Ever-smokers, Male, Never-smokers |
| polymorphism analysis | Genetic | Female, Ever-smokers, Female, Never-smokers, Male, Ever-smokers, Male, Never-smokers |
| fluorescent antibody technique | Other | Female, Ever-smokers, Female, Never-smokers, Male, Ever-smokers, Male, Never-smokers |
| immunohistochemistry staining method | Other | Female, Ever-smokers, Female, Never-smokers, Male, Ever-smokers, Male, Never-smokers |
| laboratory biomarker analysis | Other | Female, Ever-smokers, Female, Never-smokers, Male, Ever-smokers, Male, Never-smokers |
| matrix-assisted laser desorption/ionization time of flight mass spectrometry | Other | Female, Ever-smokers, Female, Never-smokers, Male, Ever-smokers, Male, Never-smokers |
| study of socioeconomic and demographic variables | Other | Female, Ever-smokers, Female, Never-smokers, Male, Ever-smokers, Male, Never-smokers |
| study of high risk factors | Procedure or surgery | Female, Ever-smokers, Female, Never-smokers, Male, Ever-smokers, Male, Never-smokers |
Primary outcome
DNA adduct levels
Time frame: End of study
Tumor tissue alterations
Time frame: End of study
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Oct 2015.
Related trials for Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Christine B. Ambrosone, PhD study chair
Roswell Park Cancer Institute
Regina M. Santella, PhD study chair
Herbert Irving Comprehensive Cancer Center
Kathy S. Albain, MD study chair
Loyola University
405 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Cancer, run by SWOG Cancer Research Network at 405 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 26 Oct 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 405 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
DNA adduct levels (time frame: End of study). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2015.